GSK China fined record sum

(Published 22 September 2014) Cite this as: BMJ 2014;349:g5799
Jane Parry
GlaxoSmithKline’s China operation has been fined $488 million after being found guilty of
bribery by the Changsha Intermediate People’s Court in Hunan province. In the closed door trial, which concluded on 19 September, five executives of GSK China Investment Company were also given suspended jail sentences of between two and four years. The former manager, Mark Reilly, was given a four year suspended sentence and will be deported. Read more here